By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celera Corporation 

1401 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-749-4200 Fax: n/a

Celera Corporation, acquired by Quest Diagnostics in May 2011, is a healthcare business that uses knowledge of human variability to provide new tests and services to personalize disease management. Our Products business develops and manufactures molecular diagnostic products that are used by hospitals and other clinical laboratories to detect, characterize, monitor and select treatment for disease. We have a distribution agreement with Abbott, through which we develop and commercialize a wide range of molecular diagnostic products, with Abbott serving as the distribution partner.

Our Services business, Berkeley HeartLab, Inc. (BHL), is a high complexity CLIA certified laboratory that offers over 25 clinical diagnostic tests including assays that determine lipoprotein particle size and density based on our proprietary segmented gradient gel electrophoresis technology, along with state-of-the-art genetic testing. These tests identify and characterize risk for cardiovascular disease and help physicians recommend treatment. Our 4myheart centers are staffed with medical professionals who use results from testing at BHL to work with patients, under their physician’s direction, to develop customized regimens for exercise, nutrition, stress management and therapy compliance.

Our internal research and partnering activities fuel the development of new diagnostic tests for personalizing disease management. These new tests are offered as products and/or services.

Key Statistics

Ownership: Public

Web Site: Celera Corporation
Symbol: CRA



Seattle Genetics  Seeking to jointly discover and develop antibody-based therapies for cancer.

Aventis Pharmaceuticals, Inc.  Aventis is investigating the use of Cathepsin S inhibitors in a number of therapeutic areas related to inflammation and autoimmune disease.

Maxim Pharmaceuticals, Inc.  Collaboration to identify and develop novel small-molecule compounds that induce apoptosis, potential new therapies for certain cancers.

Abbott  Broad program to discover, develop and commercialize therapies for the treatment of cancer, including therapeutic antibodies and small molecules.

Merck & Co.  Genome databases, Alzheimer's disease, Diagnostics

Company News
Quest Diagnostics Inc. (DGX) Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger of Celera Corporation (CRA) Stocks by Spark Acquisition Corporation 5/11/2011 6:23:26 AM
Quest Diagnostics Inc. (DGX) Extends Tender Offer for all Outstanding Shares of Celera Corporation (CRA) to May 2, 2011 4/18/2011 6:40:29 AM
Quest Diagnostics Inc. (DGX) Commences Tender Offer for Acquisition of Celera Corporation (CRA) 3/28/2011 8:57:38 AM
Quest Diagnostics India to Buy Celera Corporation (CRA) for $657 Million 3/18/2011 6:48:33 AM
Celera Corporation (CRA) Delays Filing of 2010 Form 10-K 3/10/2011 10:14:48 AM
Celera Corporation (CRA) to Webcast Presentation at JPMorgan Healthcare Conference 1/6/2011 9:44:14 AM
Celera Corporation (CRA) Files U.S. Regulatory Application for KIF6 Genotyping Assay 1/3/2011 9:26:08 AM
Celera Corporation (CRA) Announces Appointment of Alfred Merriweather as Chief Financial Officer 12/20/2010 9:25:06 AM
Celera Corporation (CRA) Reports Third Quarter 2010 Results 11/4/2010 8:36:29 AM
Celera Corporation (CRA) Posts 21 Percent Q3 Revenue Decline, Will Cut 50 Jobs 11/4/2010 7:59:47 AM